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Extracellular nucleotides are believed to be important
regulators of ion transport in epithelial tissues as a re-
sult of their ability to activate cell surface receptors.
Although numerous receptors that bind nucleotides
have been identified, the complexity of this receptor
family, combined with the lack of pharmacological
agents specific for these receptors, has made the assign-
ment of particular receptors and ligands to physiologi-
cal responses difficult. Because ATP and UTP appear
equipotent and equieffective in regulating ion transport
in many epithelia, we tested the hypothesis that the
P2Y2 receptor (P2Y2-R) subtype mediates these re-
sponses in mouse epithelia, with gene targeting tech-
niques. Mice with the P2Y2-R locus targeted and inacti-
vated (P2Y2-R(2/2)) were generated, airways (trachea),
gallbladder, and intestines (jejunum) excised, and Cl2
secretory responses to luminal nucleotide additions
measured in Ussing chambers. Comparison of P2Y2-
R(1/1) with P2Y2-R(2/2) mice revealed that P2Y2-R me-
diated most (>85–95%) nucleotide-stimulated Cl2 secre-
tion in trachea, about 50% of nucleotide responses in the
gallbladder, and none of the responses in the jejunum.
Dose-effect relationships for nucleotides in tissues from
P2Y2-R(2/2) mice suggest that the P2Y6-R regulates ion
transport in gallbladder and to a lesser extent trachea,
whereas P2Y4 and/or unidentified receptor(s) regulate
ion transport in jejunum. We conclude that the P2Y2
receptor is the dominant P2Y purinoceptor that regu-
lates airway epithelial ion transport, whereas other P2Y
receptor subtypes are relatively more important in
other nonrespiratory epithelia.
Metabotropic (G protein-coupled) P2Y receptors are ex-
pressed in epithelia and regulate epithelial ion transport and,
consequently, have become potential targets for drug therapy
of diseases that reflect abnormal epithelial ion transport (1). Of
particular interest in this context is cystic fibrosis (CF),1 a
disease that reflects widespread defects in epithelial ion trans-
port due to mutations in the cystic fibrosis transmembrane
conductance regulator (CFTR) (2). However, the spectrum of
epithelia affected by this disease (e.g. airway, gallbladder, and
intestine), the diversity of P2Y receptor subtypes (3), and the
absence of selective reagents to define which P2Y receptor
subtypes regulate ion transport have made it difficult to ini-
tiate therapeutic programs to target specific purinoceptors in
these tissues.
The strongest evidence for a role for P2 receptors in the
regulation of ion transport emanates from studies of airway
epithelia. Recent reports indicate that extracellular triphos-
phate nucleotides regulate many of the airway ion transport
paths, including slowing Na1 absorption (4) and stimulating
Cl2 and K1 secretion (5, 6). Pharmacological studies in the
human airway epithelial cell line CF/T43 have demonstrated
that UTP and ATP are equipotent and cross-desensitize in
promoting phospholipase C activity, leading to the hypothesis
that the P2Y2 receptor (P2Y2-R) is the dominant receptor me-
diating these responses (7, 8). However, it is difficult to distin-
guish whether the actions of ATP and UTP on ion transport are
mediated by a single purine/pyrimidine-sensitive receptor (e.g.
P2Y2) and/or a combination of other recently cloned P2Y recep-
tors that are potently activated by ATP (e.g. P2Y1 (9, 10), P2Y11
(11), or P2X (3, 12–14)), and UTP (e.g. P2Y4 (15, 16)).
Studies of the P2Y receptor subtypes and regulation of ion
transport in the gastrointestinal system are more limited. Data
from the murine gallbladder suggest that both ATP and UTP
are active in regulating Cl2 and HCO3
2 secretion (17, 18),
suggesting that the P2Y2-R may be the major P2Y-R subtype
regulating ion transport in this tissue. Early studies of freshly
excised rat jejunum reported regulation of ion transport by
ATP but not UTP (19). More recent studies of triphosphate and
diphosphate nucleotides in cell lines derived from the human
intestine (e.g. CaCo2 cells) suggest that ATP, UTP, and UDP
regulate enterocyte Cl2 secretory rates (20).
We report here the use of a genetic approach (21) combined
with traditional pharmacological methodologies to define the
relative role of purinoceptors in the regulation of ion transport
in epithelial tissues. Based on the reports of the actions of ATP
and UTP in the epithelia described above, a first approach was
to target a single receptor that could transduce responses to
ATP and UTP equipotently. The P2Y2-R exhibits this pharma-
cology, and, consequently, mice were generated with inacti-
vated P2Y2-R genes using the homologous recombination tech-
nique (21). Because triphosphate nucleotide effects on Cl2 and
water secretion are projected as the major therapeutic actions
of these agents in epithelial diseases such as CF (5, 22), char-
acterization of these mice focused on the role of the P2Y2
receptor in mediating epithelial Cl2 secretory responses. In a
companion paper (23), the role of P2Y2 receptor in inositol
phosphate formation and intracellular Ca21 mobilization in
tracheas and other tissues were characterized.
EXPERIMENTAL PROCEDURES
Mice Used for Phenotypic Characterization—Adult mice (wild type
and P2Y2-R(2/2)) of both sexes were used in this investigation. All
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animals were bred and raised at the University of North Carolina. The
mean body mass of the normal animals (32.4 6 1.8 g, n 5 20) was not
significantly different from the mean body mass of the littermate P2Y2-
R(2/2) mice (34 6 1.9 g, n 5 21). All mice were allowed food and water
ad libitum until euthanized.
Mice were euthanized with 100% CO2, and the tracheas, intestine,
and gallbladders were quickly excised. The trachea was dissected free of
vessels and connective tissue, split longitudinally along the posterior
surface, and mounted in Ussing chambers (24). The gallbladder was
opened, irrigated to remove bile, and mounted as a flat sheet in an
Ussing chamber. Because of the fragility of gallbladders, a cellulose
mesh was placed over the aperture of the Ussing chamber (serosal side
only) to prevent the tissue from falling through the aperture. Both
tissues were mounted on Ussing chambers having an aperture surface
area of 0.025 cm2. The techniques for mounting the intestinal tissue
(0.25-cm2 aperture Ussing chamber) have been previously described
(25). Parafilm “O” rings were placed on both sides of the tissues to
reduce edge damage.
Bioelectric Measurements—Electrical measurements of tissues were
made under short circuit (Isc) conditions as previously reported (24, 26).
Tissues were bathed bilaterally in gassed (95% O2, 5% CO2) Krebs
bicarbonated Ringer solution having the following composition: 140 mM
Na1, 120 mM Cl2, 5.2 mM K1, 1.2 mM Mg21, 1.2 mM Ca21, 2.4 mM
HPO4
22, 0.4 mM H2PO
42, 25 mM HCO3
2, and 5 mM glucose. Amiloride
(1024 M; Sigma) was added to the luminal side of all tracheas to block
Na1 absorption, which allows Cl2 secretory responses to agonists to be
studied (24). Since the gallbladder and jejunum were unresponsive to
amiloride, this drug was omitted from the protocols involving these
tissues. Tissues were allowed to stabilize for 30 min before the first
measurements were made or drugs added. Short circuit (Isc) was con-
tinuously recorded and resistance calculated by Ohm’s law by meas-
uring the Isc change in response to a 1-mV constant voltage pulse (26).
All additions were to the luminal bath.
Protocols—For the dose-response studies, each dose was added cu-
mulatively to the luminal surface of the tissue. When the tissue re-
sponded to the agonist, the response was immediate. After the response
had peaked and/or stabilized (usually 2–3 min), the next dose was
added. The response to the added agonist was determined as a change
in the Isc from the basal or previous dose level. For studies of the P2Y1
antagonist A3P5P in jejunum, tissues were pretreated with A3P5P
(1024 M) in the luminal solution prior to nucleotide additions.
Materials—ATP and UTP were purchased from Amersham Pharma-
cia Biotech (Uppsala, Sweden), A3P5P was from Sigma, a,b-methylene
ATP (a,b-meATP), 2-methylthio-ATP (2-MeSATP), and 2-methylthio-
ADP (2-MeSADP) from RBI (Natick, MA), and UDP and adenosine from
Roche Molecular Biochemicals. Because UTP could potentially contam-
inate commercial preparations of UDP, and to prevent formation of
UTP from UDP via nucleoside diphosphokinase and endogenously re-
leased ATP, hexokinase (10 units/ml) and glucose (25 mM) were present
in all UDP stocks, and the purity of UDP was monitored by high
pressure liquid chromatography (27).
Data Analysis/Statistics—For all tissues, data are expressed in
terms of Isc. This Isc response is generated primarily by Cl
2 secretion
and to a lesser extent HCO3
2 secretion.2 Therefore, here the DIsc is often
referred to as Cl2 secretion. Apparent EC50 values represent the con-
centration of agonist that generated either 50% of the maximal re-
sponse or, if saturation was not achieved, 50% of the response to 1024 M.
All data are expressed as mean 6 S.E. Statistical analyses were per-
formed with nonpaired Student’s t tests.
RESULTS
Tracheal Epithelium
Characterization of Wild Type (1/1) Freshly Excised Murine
Tracheal Responses to Nucleotides—The cumulative dose-effect
relationships for six different nucleotides which are known to
be agonists at different P2 receptors versus tracheal Cl
2 secre-
tion rates (DIsc) are shown in Fig. 1A; ATP and UTP were
nearly equipotent and were the most effective agonists for the
induction of Cl2 secretion. Table I shows that in addition to
ATP and UTP, only UDP elicited a saturable Cl2 secretory
response within the micromolar concentration range (,1024 M)
(27). The maximal effect of UDP was small (;20%) compared
with ATP/UTP responses. The weak effect of 2-MeSADP or
2-MeSATP suggested that it was unlikely that ATP responses
were primarily mediated by a P2Y1 receptor. Adenosine was
also relatively ineffective (;15% of maximal ATP response; DIsc
5 36 6 11 mAzcm2 at 1024 M, n 5 5). These data suggest that
the P2Y2 receptor may be the dominant receptor in airway
epithelia of the murine trachea but that a receptor that is
activated by UDP (e.g. P2Y6) is also expressed in this tissue.
As a second approach to identify individual P2 receptors in
wild type mouse trachea, cross-desensitization studies were
performed. The initial analysis of the interactions suggests
that there is cross-desensitization between ATP and UTP; the
ATP response was abolished by UTP pretreatment (Fig. 1B),
and the UTP response was abolished by ATP pretreatment
(Fig. 1C), consistent with interaction of both ligands at a single
(P2Y2) receptor.
However, this interpretation was complicated by the obser-
vation that both agonists produced large maximal responses
(.200 mAzcm22), suggesting that the failure to observe a second
response could reflect a ceiling effect and/or desensitization of
other effectors in the Cl2 secretory pathway. This possibility
was supported by the observations that (i) UDP responses also
were abolished by ATP or UTP pretreatment (Fig. 1D) and (ii)
the actions of the muscarinic receptor agonist carbachol were
reduced after exposure of the tissue to either ATP or UTP as2 B. R. Grubb, unpublished observations.
FIG. 1. Mouse tracheas: wild type (P2Y2-R(1/1)). A, Isc dose
response to the indicated nucleotides. Data are means 6 S.E., n 5 6 at
each dose. B, desensitization of tracheal ATP responses. Isc responses to
1024 M ATP were measured in tracheas that were pretreated with no
other nucleotide (None, n 5 7) or that were pretreated with 1024 M UTP
(n 5 4), UDP (n 5 3), or 2-MeSATP (n 5 3). C, desensitization to UTP
responses. Isc responses to 10
24 M UTP were measured in tracheas that
were pretreated with no other nucleotide (None, n 5 7) or that were
pretreated with 1024 M ATP (n 5 4), UDP (n 5 3), or 2-MeSATP (n 5 2).
D, desensitization to UDP responses. Isc responses to 10
24 M UDP were
measured in tracheas that were pretreated with no other nucleotide
(None, n 5 6) or that were pretreated with 1024 M ATP (n 5 3), UTP
(n 5 3), or 2-MeSATP (n 5 3). p # 0.05. Data in all bar graphs are
means 6 S.E.
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pretreatment (Dcarbachol (1024 M) naive 5 62 6 3.3 mAzcm22;
Dcarbachol (1024 M) post-ATP (1024 M) 5 19 6 5 mAzcm22).
Thus, it is not clear whether the reduced effects of UTP post-
ATP indicate desensitization of a common receptor for these
nucleotides (e.g. P2Y2) or whether activation of, for example, a
uridine-selective receptor (e.g. P2Y4 or P2Y6) is masked by the
ceiling effect of ATP acting on an ATP-selective receptor (e.g.
P2Y11 or P2X receptor). Moreover, since P2Y4, P2Y6, and P2Y11
receptors are not pharmacologically defined in the mouse, we
cannot rule out the possibility that either of these receptors is
activated by ATP, UTP, and UDP. The modest inhibition of the
ATP response by 2-MeSATP pretreatment (Fig. 1B) without
any effect on UTP or UDP responses (Fig. 2, C and D) raises the
possibility of a low level of functional expression of a P2Y1
receptor in murine trachea.
In summary, it is difficult from the above data to distinguish
whether a single receptor, e.g. P2Y2, or a mixture of receptors
accounted for all of the effects observed with the six agonists
tested. In an attempt to resolve these issues, a comparable
characterization of the nucleotide responses of P2Y2-R(2/2)
mouse tracheas was performed.
Characterization of P2Y2-R(2/2) Freshly Excised Tracheas—
Fig. 2A shows the cumulative dose-effect relationships for the
six nucleotides versus Cl2 secretion (DIsc) for the tracheas from
P2Y2-R(2/2) mice plotted on the same scale as for wild type
(1/1) mice. There were major (more than 85–95%) reductions
in the Cl2 secretory responses to UTP and ATP at all concen-
trations tested. Further, there were major reductions in the
magnitude of the responses to a,b-meATP, 2-MeSATP, and
2-MeSADP (Table I), indicating that these P2X and P2Y1 re-
ceptor agonists (or contaminants), at high concentrations, also
interact with the P2Y2 receptor. No reduction in Cl
2 secretory
responses to UDP was observed relative to wild type, P2Y2-
R(1/1) mice (Table I).
To verify that the P2Y2-R disruption did not affect the Cl
2
secretory capacity of the trachea, we compared responses to
carbachol. Carbachol (1024 M) was equieffective in P2Y2-
R(1/1) (62 6 3 mAzcm22) and P2Y2-R(2/2) mice (63 6 2
mAzcm22), suggesting that the Cl2 secretory capacity of the
trachea was not decreased by targeting the P2Y2 locus (n 5 4,
both groups).
The calculated EC50 values, the magnitude of the maximal
response, and the percentage reduction in the maximal re-
sponses for the P2Y2-R(2/2) mice as compared with wild type
mice (Table I) clearly indicate that the P2Y2 receptor is the
dominant receptor in the murine trachea that transduces the
administration of triphosphate nucleotides to the tracheal ep-
ithelial surface into Cl2 secretory responses.
A variety of protocols were employed in an attempt to iden-
tify the residual receptors expressed in the P2Y2-R(2/2) mouse
trachea. These protocols were in general difficult because of the
small magnitude of the Cl2 secretory responses mediated by
residual receptors and the failure of most agonists to reach
saturating concentrations within the submillimolar range.
UDP responses in the tracheal preparations were not af-
fected by the P2Y2 receptor disruption (Table I), suggesting
that a functional P2Y6 receptor is expressed in this tissue.
Since P2Y6 receptors are activated, although weakly, by ADP
(28), a portion of the small residual ATP effect could reflect
extracellular conversion of ATP to ADP (29). However, al-
though ATP inhibits UDP-evoked responses (Fig. 2D), UDP
does not affect subsequent responses to ATP (Fig. 2B). This
FIG. 2. Mouse tracheas: P2Y2-R(2/2). A, Isc dose response to the
indicated nucleotides. Data are means 6 S.E., n 5 6 at each dose. B,
desensitization to ATP responses. Isc responses to 10
24 M ATP were
measured in tracheas that were pretreated with no other nucleotide
(None, n 5 10) or that were pretreated with 1024 M UTP (n 5 4), UDP
(n 5 3), or 2-MeSATP (n 5 3). C, desensitization to UTP responses. Isc
responses to 1024 M UTP were measured in tracheas that were pre-
treated with no other nucleotide (None, n 5 7) or that were pretreated
with 1024 M ATP (n 5 3), UDP (n 5 3), or 2-MeSATP (n 5 3). D,
desensitization to UDP responses. Isc responses to 10
24 M UDP were
measured in tracheas that were pretreated with no other nucleotide
(None, n 5 6) or that were pretreated with 1024 M ATP (n 5 3), UTP
(n 5 3), or 2-MeSATP (n 5 3). Data in all bar graphs are means 6 S.E.
TABLE I
Agonist responses in mouse tracheas
n is shown in parentheses.
Agonist
Wild-type P2Y2-R(2/2) Decrease of
maximum responseMaximum response Apparent EC50 Maximum response Apparent EC50
1024 M 1024 M %
ATP 229.5 6 73 (7) 6 3 1027 12.7 6 3.1 (7) 2 3 1026 94.8a
UTP 191.5 6 37 (7) 8 3 1027 33 6 9.9 (7) 2 3 1027 83b
UDP 43.6 6 9.8 (6) 5 3 1026 39.4 6 13.6 (6) 6 3 1027 10
a,b-meATP 58.1 6 29 (3) .1025 5.2 6 5.2 (3) .1025 91
2-MeSATP 84.5 6 17.1 (3) .1025 13.6 6 0.8 (3) 2 3 1026 84
2-MeSADP 37.1 6 3.9 (3) .1025 17.2 6 7.4 (3) 3 3 1026 54
a p # 0.01.
b p # 0.001.
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finding suggests that ATP could affect UDP responses by a
different mechanism, e.g. ATP-dependent removal of UDP by
ectonucleoside diphosphokinase (27).
A small residual effect of UTP was also observed in the
P2Y2-R 2/2 tracheal epithelia (Fig. 2 and Table I), which was
mostly inhibited by pretreatment with UDP. This residual
effect of UTP could reflect either extracellular conversion of
UTP to UDP or direct activation of murine P2Y6 receptors by
UTP. The attenuation of UDP-promoted responses by UTP
supports either of these possibilities.
Finally, the residual ATP effects were very small. The equi-
potency and equieffectiveness of 2-MeSADP (and 2-MeSATP)
with ATP (Table I) suggest that this small residual effect may
reflect a P2Y1-R-like activity.
Gallbladder
Characterization of Nucleotide- stimulated Cl2 Secretion in
Wild Type (P2Y2-R(1/1)) Freshly Excised Gallbladders—We
next tested for the effect of nucleotides on the freshly excised
murine gallbladder (Fig. 3). These data differ from the freshly
excised trachea in one striking respect, i.e. UDP was virtually
equieffective and equipotent with ATP and UTP in initiating a
secretory response (DIsc) in this tissue (Fig. 3A, Table II). 2-Me-
SADP induced a small response (;40% of ATP response),
which was only attained at high micromolar concentrations.
2-MeSATP and a,b-meATP were entirely without effect in this
tissue (Table II). Unlike the trachea, adenosine was completely
ineffective (DIsc 5 3.9 6 2.8 mAzcm
2 at 1024 M, n 5 3).
Fig. 3, B–D, displays cross-desensitization protocols. UTP
but not UDP partially blocked the subsequent response to ATP,
and ATP largely attenuated the subsequent response to UTP
but not to UDP, consistent with an interaction of ATP and UTP
at a P2Y2 receptor. UDP attenuated the subsequent response to
UTP but not to ATP (Fig. 3, B and C), and UTP blocked the
subsequent response to UDP (Fig. 3D).
In summary, the data indicate the possible expression of a
P2Y2 and a P2Y6 receptor in the murine gall bladder epithe-
lium. To test this hypothesis more rigorously, we characterized
the effect of nucleotides on the gallbladder epithelial cells from
the P2Y2-R(2/2) mouse.
Characterization of P2Y2-R(2/2) Freshly Excised Gallblad-
der (Fig. 4)—Disruption of the P2Y2-R gene in the gallbladder
revealed that the responses to ATP were virtually abolished in
the P2Y2-R(2/2) gallbladders. In contrast, the effect of UTP
was only partially reduced (30%) in the P2Y2-R(2/2) gallblad-
der cells relative to the wild type cells, whereas the UDP
responses were not affected by the P2Y2-R disruption (Table
II).
Studies of interactions with the residual ATP responses were
not informative because of the very small magnitude of these
residual responses (Fig. 4). With respect to UTP, the relatively
large (70% of wild type) residual UTP response was blocked by
UDP but not ATP (or 2-MeSATP) pretreatment (Fig. 4C). Sim-
ilarly, the persistent UDP response was inhibited by UTP but
not adenine nucleotide pre-treatment (Fig. 4D). These data
suggest that a common receptor transduces the P2Y2-R(2/2)
gallbladder UDP/UTP response. The P2Y6-R is a candidate for
this function.
Jejunum
Effect of Nucleotides on Cl2 Secretory Responses in Normal
(P2Y2-R(1/1)) Jejuna—The luminal dose-response curve de-
scribing the actions of ATP, UTP, ADP, and UDP on freshly
excised normal mouse jejuna are shown in Fig. 5A. Several
points deserve comment. First, unlike the tracheal and gall-
bladder preparations, approximately 25–30% of the normal
jejunal preparations failed to respond to any nucleotide. These
preparations were viable, since they had a normal response to
forskolin. The nonresponding preparations were omitted from
the analysis. Second, the dose-effect relationships for all the
effective agonists were somewhat shifted to the right (see Table
III for EC50 values) as compared with the activities in the
gallbladder and trachea. Third, as in the other tissues, ATP
and UTP were approximately equieffective and equipotent ago-
nists at the luminal jejunum surface. Fourth, uniquely in the
jejunum, ADP was also nearly as effective and potent as ATP
and UTP. In contrast to the gallbladder and trachea, UDP
appeared to be weak and relatively ineffective. Adenosine (1024
M) was ineffective (DIsc 5 9 6 5 mAzcm
2, n 5 3) in jejunum.
Based simply on the agonist dose-effect curves, it seems rea-
sonable to postulate that both P2Y2 (ATP/UTP)-like and per-
haps P2Y1-like (ADP) activities are expressed in jejuna.
Cross-desensitization experiments (Fig. 5B) suggested that
UTP desensitized the subsequent ATP responses and that the
converse was also true, consistent with the possibility that
P2Y2 receptors transduce ATP/UTP responses. However, the
ceiling effect described earlier may be an equally likely alter-
native explanation for these results.
Effect of Nucleotides on Cl2 Secretory Response in P2Y2-
R(2/2) Mouse Jejuna—In contrast to the data from the P2Y2-
FIG. 3. Mouse gallbladders: wild type (P2Y2-R(1/1)). A, Isc dose
response to the indicated nucleotides. Data are means 6 S.E., n 5 6 at
each dose. B, desensitization to ATP responses. Isc responses to 10
24 M
ATP were measured in gallbladders that were pretreated with no other
nucleotide (None, n 5 7) or that were pretreated with 1024 M UTP (n 5
4), UDP (n 5 3), or 2-MeSATP (n 5 3). C, desensitization to UTP
responses. Isc responses to 10
24 M UTP were measured in gallbladders
that were pretreated with no other nucleotide (None, n 5 6) or that were
pretreated with 1024 M ATP (n 5 5), UDP (n 5 3), or 2-MeSATP (n 5 2).
D, desensitization to UDP responses. Isc responses to 10
24 M UDP were
measured in gallbladders that were pretreated with no other nucleotide
(None, n 5 6) or that were pretreated with 1024 M ATP (n 5 3), UTP
(n 5 3), or 2-MeSATP (n 5 3). *, p # 0.05 compared with result with no
nucleotide pretreatment (None). Data in all bar graphs are means 6
S.E.
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R(2/2) trachea and gallbladder, the Cl2 secretory responses to
nucleotide additions in the P2Y2-R(2/2) jejuna were not dif-
ferent from the wild type mice (Fig. 6A). Like the P2Y2-R(1/1)
jejuna, approximately 25–30% of the P2Y2-R(2/2) jejuna failed
to respond to any nucleotide and were omitted from the data
analyses. For the responders, the potency of ATP and UTP and
the magnitude of the Cl2 secretory responses to these agonists
in P2Y2-R(2/2) mice were virtually identical to those of the
wild type mice (see Table III).
Like the P2Y2-R(1/1) jejuna, smaller responses to the sec-
ond triphosphate nucleotide were observed in the P2Y2-R(2/2)
jejuna after the addition of a maximal dose of a first triphos-
phate nucleotide (Fig. 6B). This “desensitization” may reflect
homologous desensitization of a novel P2Y2-R-like receptor (see
below), a ceiling effect, or heterologous desensitization between
an ATP and an UTP receptor. Since pretreatment with the
P2Y1-R antagonist A3P5P (30) was without effect on ADP/ATP
responses (Fig. 7), it is unlikely that the persistent ADP/ATP
responses were mediated by P2Y1-R.
DISCUSSION
Numerous studies report that both purine and pyrimidine
triphosphate nucleotides regulate epithelial ion transport. Be-
cause the P2Y2 receptor was the first receptor cloned that was
activated by both pyrimidine and purine nucleotides, many
TABLE II
Agonist responses in mouse gallbladders
n is shown in parentheses.
Agonist
Wild-type P2Y2-R(2/2) Decrease of
maximum responseMaximum responses Apparent EC50 Maximum responses Apparent EC50
1024 M 1024 M %
ATP 80.3 6 13.2 (7) 3 3 1026 9.9 6 2.7 (7)a 1 3 1026 88b
UTP 71.3 6 4.8 (6) 3 3 1026 50.5 6 9.3 (7) 2 3 1026 29 NSc
UDP 54.6 6 11.5 (6) 1 3 1026 55.1 6 4.3 (8) 2 3 1026 0
a,b-meATP 1.9 6 1.9 (3) .1025 0 6 0 (3) 100
2-MeSATP 0 6 0 (3) 0 6 0 (3)
2-MeSADP 31.2 6 4.4 (3) .1025 9.7 6 2.6 (3)b .1025 69d
a —.
b p # 0.001.
c Not significant.
d p # 0.01.
FIG. 4. Mouse gallbladders: P2Y2-R(2/2). A, Isc dose response to
the indicated nucleotides. Data are means 6 S.E., n 5 6 at each dose. B,
desensitization to ATP responses. Isc responses to 10
24 M ATP were
measured in gallbladders that were pretreated with no other nucleotide
(None, n 5 7) or that were pretreated with 1024 M UTP (n 5 5), UDP
(n 5 3), or 2-MeSATP (n 5 3). C, desensitization to UTP responses. Isc
responses to 1024 M UTP were measured in gallbladders that were
pretreated with no other nucleotide (None, n 5 7) or that were pre-
treated with 1024 M ATP (n 5 6), UDP (n 5 3), or 2-MeSATP (n 5 2). D,
desensitization to UDP responses. Isc responses to 10
24 M UDP were
measured in gallbladders that were pretreated with no other nucleotide
(None, n 5 8) or that were pretreated with 1024 M ATP (n 5 3), UTP
(n 5 3), or 2-MeSATP (n 5 3). *, p # 0.05 compared with pretreatment
with no other nucleotide. Data in all bar graphs are means 6 S.E.
FIG. 5. Mouse jejuna: wild type P2Y2-R(1/1). A, Isc dose response to
the indicated nucleotides. n 5 6 or more at each dose. B, desensitization
study of response to ATP after treating tissue with 1024 M UTP (n 5 5).
None refers to ATP response without pretreatment with another nucle-
otide (n 5 6). p # 0.05. C, desensitization study of response to UTP after
pretreating the tissue with ATP (1024 M). n 5 8. None, n 5 8. *, p # 0.05.
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studies have tentatively identified P2Y2-R as the receptor me-
diating epithelial ion transport responses to triphosphate nu-
cleotides. Based on comparisons of Cl2 secretory responses in
P2Y2-R(1/1) and P2Y2-R(2/2) mice, a surprisingly wide spec-
trum in the P2Y2-R contribution to ATP/UTP regulated ion
transport was observed in the three different epithelia studied.
The contribution ranged from P2Y2-R, being the dominant
ATP/UTP receptor in tracheal epithelia, to the gallbladder,
where P2Y2-R appeared to transduce about 50% of the triphos-
phate nucleotide responses, to the intestine, where P2Y2-R
appeared to transduce virtually none of the triphosphate nu-
cleotide actions.
These observations led to studies designed to identify the
P2Y receptors in addition to P2Y2-R that regulate ion transport
in mouse epithelia. The following are candidate P2Y receptors
that may participate in this regulation, based on reports of
studies of cloned human P2 receptors: P2Y1, which has a rank
order potency of 2-MeSADP . ADP . 2-MeSATP . ATP (10,
31, 32); P2Y4, which is activated by UTP but not by ATP (15,
16), P2Y6, which has a rank order of potency of UDP .. ADP
.. UTP/ATP (28, 33), and P2Y11-R, which has a rank order
potency of ATP . 2-MeSATP and is not activated by ADP,
UDP, or UTP (11). A problem, however, in assigning a response
to these previously characterized P2 receptors is that homolo-
gous murine P2 receptors have not been pharmacologically
characterized in detail. For instance, it is not known whether
UDP is an agonist at the cloned mouse P2Y2 receptor (34) and
what is the rank order of potencies for ATP and ADP at the
cloned mouse P2Y1 receptor (32). The importance of rodent
data is highlighted by the recent report that the rat P2Y4
receptor is activated equipotently by ATP and UTP (35, 36).
Additional concerns in a pharmacological characterization of
P2 receptor activity are data indicating that agonists may not
be receptor-specific. For example, a,b-meATP, which was orig-
inally thought be a specific and potent agonist for P2X recep-
tors (37), is only a relatively weak agonist at the P2X1 and P2X3
receptors (38–40), while 2-MeSATP, which was originally de-
scribed as a selective P2Y (P2Y1) receptor agonist (37), is a
TABLE III
Agonist response in mouse jejunum
n is shown in parentheses.
Agonist
1/1 2/2
Maximum response Apparent EC50 Maximum response Apparent EC50
1023 M
ATP 131.5 6 27 (5) 3 3 1025 110.4 6 26 (5) 2 3 1025
UTP 116.7 6 15.5 (4) 1025 136 6 40 (3) 1025
UDP 42.7 6 16.7 (3) 3 3 1024 41.5 6 6.4 (4) 3 3 1024
ADP 107.4 6 35 (4) 5 3 1025 100 6 37 (4) 4 3 1025
FIG. 6. Mouse jejuna, P2Y2-R(2/2). A, Isc dose response to the
indicated nucleotides. n 5 6 or more at each dose. B, desensitization
study of response to ATP, after pretreating tissue with 1024 M UTP (n 5
5). None refers to ATP response without pretreatment with another
nucleotide (n 5 5). p # 0.05. C, desensitization study of response to UTP
after pretreating the tissue with ATP (1024 M). n 5 8. None, n 5 7. *, p #
0.05.
FIG. 7. Lack of effect of P2Y1-R antagonist (A3P5P) on jejunal
Cl2 secretory responses to adenine nucleotides. A, ATP response
of P2Y2-R(2/2) jejuna in the presence and absence of A3P5P. B, ADP
response of P2Y2-R(2/2) jejuna in the presence and absence of A3P5P.
All drugs were at a concentration of 1024 M (n 5 5 for each point).
P2Y2 Receptor-regulated Ion Transport26466
potent agonist at most P2X receptor subtypes (41). The avail-
ability of mice with the P2Y2-R gene inactivated greatly sup-
plemented our pharmacological approaches to identification of
the roles of other P2Y receptors in nucleotide-mediated regu-
lation of ion transport.
The concept of nucleotide-based pharmacotherapy for CF
airways disease has emphasized the importance of defining the
specific purinoceptor that mediates activation of Cl2 secretion
in this tissue (1). The data that describe the interactions be-
tween these ligands and tracheal Cl2 secretory rates in wild
type mice (Fig. 1) demonstrate the difficulty in using strictly
pharmacological approaches (e.g. a combination of agonist
dose-response curves and desensitization protocols) to assign a
specific P2Y receptor subtype to an ion transport regulatory
function. However, the combination of the Cl2 secretion (Figs.
1 and 2) and Ca21i data from a companion paper (23) compar-
ing the wild type with P2Y2-R(2/2) mice provide strong evi-
dence for the first definitive assignment of P2Y2-R to a physi-
ologic function. Thus, although costly and time-consuming, the
gene targeting technique appears to be the unique approach for
unambiguously defining P2Y2 receptor function in specific
tissues.
There were small (;15% of P2Y2-R(1/1) responses) residual
ATP and UTP Cl2 secretory responses in the P2Y2-R(2/2)
trachea as well as a small, persistent UDP response. The de-
tection of a relatively high potency UDP response (EC50 of
;1026 M, Table I) in the P2Y2-R(1/1) mouse trachea and its
persistence in the P2Y2-R(2/2) mouse suggest that a P2Y6
receptor mediated the UDP response. This observation is con-
sistent with recent evidence of the expression of a UDP recep-
tor in human airway epithelia (27). Data describing the equi-
potency of 2-MeSATP and ATP (Table I), coupled with their
cross-desensitization (Figs. 1 and 2), suggest that the P2Y1-R,
a P2X-R, or the P2Y11-R accounted for the very small residual
ATP responses in the P2Y2-R(2/2) trachea. The results of
intracellular Ca21 studies in the companion paper (23) favor
P2Y1-R as the “other” P2 receptor.
Investigations of purinoceptor regulation of gallbladder Cl2
secretion have focused on triphosphate nucleotides (17, 18, 42).
In the wild type murine gallbladder, both ATP and UTP were
equipotent and effective agonists, consistent with a P2Y2 re-
ceptor-mediated response (Fig. 3, Table II). The effectiveness
and potency of UDP was consistent with regulation of Cl2
secretion in P2Y2-R(1/1) mouse gallbladder by a P2Y6 recep-
tor. An apparent major difference between the gallbladder and
the trachea is that 2-MeSATP or 2-MeSADP were ineffective in
gallbladder (Fig. 3), indicating that the P2Y1 receptor (and
P2Y11-R) are not functionally expressed in this tissue.
The data from the P2Y2-R(2/2) gallbladder indicate that
virtually all of the ATP regulation of Cl2 transport is mediated
via the P2Y2-R. These findings were further supported by the
absence of effectiveness of P2Y1-R agonists and adenosine. In
contrast, about 70% of the UTP response persisted. The cross-
desensitization protocols with UDP and the potency order
UDP . UTP suggested, but do not prove, that both the diphos-
phate and triphosphate pyrimidine nucleotide responses are
mediated by the P2Y6-R and point to the need for cloning and
characterizing the mouse P2Y6-R (as well as the mouse P2Y4
receptor). These data suggest a role for released pyrimidines as
well as purines in the regulation of gallbladder ion transport
rates.
In wild type mice, the equipotency of ATP and UTP, coupled
with the partial cross-desensitization, suggested that the
P2Y2-R transduced the Cl
2 secretory responses to both purine
and pyrimidine triphosphate nucleotides in jejunal epithelium
(Fig. 5). We do not know why the potencies for all nucleotide
agonists were shifted to the right (Fig. 5 and 6), but we spec-
ulate that this shift could reflect diffusion barriers, e.g. mucus,
or high rates of cell surface nucleotide catabolism. These data
contrast with previous studies in freshly excised rat and guinea
pig intestines, which had suggested a regulatory role of ATP,
but not UTP, in ion transport (19, 43). However, the data from
the P2Y2-R(2/2) mouse unequivocally established that these
responses in mice were not transduced by the P2Y2 receptor
(Fig. 6; Table III). This observation requires an analysis of
other P2Y receptors that transduce both purine and pyrimidine
responses.
It appears unlikely that the UTP response is transduced by
the P2Y6 receptor, because UDP appeared to be a relatively
ineffective agonist in jejunal epithelium and the UTP responses
were brisk (Figs. 5 and 6). It is possible that UTP responses
were transduced by a P2Y4-like receptor. If the mouse P2Y4-R
exhibits a pharmacology similar to the rat P2Y4 receptor (i.e.
UTP 5 ATP), the simplest hypothesis is that mouse jejunal ion
transport is functionally regulated by ATP and UTP via
P2Y4-R. Alternatively, if the mouse P2Y4-R behaves like the
human P2Y4-R, i.e. UTP .. ATP, ATP and UTP might act on
different receptors, which cross-desensitize each other.
The effectiveness of ADP in stimulating jejunal Cl2 secretion
suggested the presence of a P2Y1 receptor. However, it is un-
likely that ADP (or ATP) was interacting with a luminal
P2Y1-R because of the failure of A3P5P to block these responses
(44). Moreover, previous reports indicating a predominantly
basolateral expression of P2Y1-R in other epithelia (e.g. air-
ways (45)) suggest that the P2Y1 receptor was not involved in
the Cl2 responses to luminal ADP and ATP.
There is little precedent for an ADP-stimulated response not
mediated by the P2Y1 receptor. The most notable action of ADP
on receptors other than the P2Y1 receptor occurs in platelets.
ADP-promoted platelet shape change and aggregation involves
three independent receptors: the P2Y1 receptor, a P2X recep-
tor, and a yet unidentified receptor that couples to inhibition of
adenylyl cyclase (46). In rat C6 glioma cells, ADP also potently
promotes inhibition of adenylyl cyclase by a mechanism that is
independent from the P2Y1 receptor (10). Besides these obser-
vations, there are no obvious additional candidates other than
novel P2 receptors to mediate the jejunal response to ADP.
We conclude that the jejunal epithelium transduces Cl2 se-
cretory responses to luminal nucleotides by a quite different set
of receptors than are expressed on the tracheal or gallbladder
epithelium. The effectiveness of luminal ADP in stimulating
jejunal Cl2 secretion had not been reported in gut epithelia
previously and was unique in the epithelia we surveyed. These
observations may have important implications for potential
therapies directed at this epithelium.
In summary, these studies of tissues excised from P2Y2 re-
ceptor deficient mice have identified a functional role for the
P2Y2 nucleotide receptor subtype in the regulation of ion se-
cretion. These studies have also demonstrated a diverse role for
the P2Y2-R in this activity, the contribution being dominant in
airways, intermediate in the gallbladder, and absent in the
jejunum. Further, by eliminating the P2Y2-R from tissues, the
studies have led to hypotheses that other P2Y receptor sub-
types have ion transport regulatory activities in these epithe-
lia. For example, we speculate that the P2Y6-R performs a
relatively large (gallbladder) and small (trachea) ion transport
regulatory function in some epithelia, whereas the P2Y4-like
receptors are more important in others, e.g. jejunum. Since
airways presently constitute the primary target for nucleotide
therapy of CF (1) and targeting a specific P2Y receptor subtype
linked to Cl2 secretion would appear to be an optimal strategy,
these data support the notion of the development of potent and
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selective agonists for the P2Y2 receptor as potential therapies
of CF lung disease and expand the spectrum of receptor targets
for other epithelia.
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